Navigation Links
Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
Date:2/15/2012

/b>, Pennsylvania State University: "We recently found evidence for a link between inherited variations in sensitivity to male sex hormones (androgens) and some aspects of lupus in men. Our LRI study is exploring for the first time how differences in sensitivity to androgens might promote autoimmunity by allowing B cells to more easily switch to production of disease-causing autoantibodies. Since these same hormones are present in much lower amounts in women, we're also looking at whether such inherited differences in androgen sensitivity might influence the course of lupus in women."

Understanding Organ Damage

Three investigators will explore how the lupus immune system damages specific organs.  

  • Dr. Meggan Mackay, The Feinstein Institute of Medical Research: "This brain imaging study is the first testing whether autoantibodies against neurotransmitter receptor NMDA impair its activation. With Feinstein neuroimaging experts, we're using a new radiochemical tracer that binds the NMDA receptor to visualize receptor activity in the brains of lupus patients with this autoantibody. If successful, the technology will be developed as a new biomarker to diagnose neuropsychiatric lupus and monitor therapy response."
  • Dr. Mariana Kaplan, University of Michigan: "Our study lays the groundwork for therapies preventing cardiovascular disease in lupus. We're building on LRI-funded work showing high-density lipoprotein (HDL), 'good cholesterol,' is a risk factor for lupus-related cardiovascular disease. We're investigating in patients whether inflammation damages HDL, disrupting its protective effects on the heart and blood vessels."
  • Dr. Sandra Wolin, Yale University: "How does sunlight cause lupus skin flares? Many patients with lupus of the skin produce antibodies against a protein, Ro60, which normally binds RNA i
    '/>"/>

SOURCE Lupus Research Institute
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
3. Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
4. Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
5. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
6. Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus
7. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
8. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
9. Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment
10. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
11. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 24, 2013 Die Übersetzungen wurden ... Bei der englischen Version handelt es ... % der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren ... GINA [*] -Definition [1] als kontrolliert gelten können ... generell einer von vier Denkweisen zugeordnet werden können, die ...
(Date:5/23/2013)... stopped breathing, his collapsed bronchus blocking the crucial flow ... watched helplessly, just praying that somehow the dire predictions ... had a good chance of not leaving the hospital ... Kaiba. "At that point, we were desperate. Anything that ... it." , They found hope at the University of ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... who have been dreaming of mobile devices that run ... wish has been granted. University of Illinois engineers ... is faster and uses 100 times less energy than ... devices much longer battery life between charges. Led ...
... Inc. (Nasdaq: MYL ) today announced that ... from the U.S. Food and Drug Administration (FDA) under ... its New Drug Application (NDA) for Zidovudine Tablets, 100 ... drug Retrovir® Tablets, by ViiV Healthcare. This pediatric antiretroviral ...
... (Nasdaq CM: INSMD), a biopharmaceutical company, today reported results ... 2010. Key Recent Highlights: ... 2011 with the FDA to begin a phase 3 ... non-TB Mycobacteria (NTM) lung infections. Successfully concluded 72 ...
Cached Biology Technology:New technology would dramatically extend battery life for mobile devices 2New technology would dramatically extend battery life for mobile devices 3Mylan's Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg 2Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 8
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... fruit, can be made both better-tasting and longer-lasting thanks ... "Working with GM tomatoes that are different to normal ... allows us to pinpoint exactly how to breed in ... Innes Centre. , The research could also lead to ... characteristics because even higher levels of the compounds can ...
(Date:5/23/2013)... Laboratory honored more than 165 staff for their ... PNNL,s annual Intellectual Property Commercialization Recognition & Rewards ... national laboratory named materials scientist Jun Liu Inventor ... materials that can store large amounts of energy, ... the time it takes to charge cell phones, ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... Institute, an NCI-designated cancer center at NYU Langone Medical ... Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and ... published in the November 23 issue of Nature ... development of lymphomagenesis. "We have discovered that ...
... 28, 2011) -- Scientists at Weill Cornell Medical College used ... specially engineered for the study of cleft lip and cleft ... or treat the conditions in humans. Cleft lip and ... treatment requiring multiple cycles of surgery, speech therapy and orthodontics. ...
... published by Pensoft reported a substantial growth in 2011, ... jubilee 150th issue, By the end of November 2011, the ... compare with 4,962 pages and 180 articles in 2010). Since ... than 19,000 pages and 780 articles of valuable information on ...
Cached Biology News:New potential therapeutic target identified for Diffuse Large B-Cell Lymphoma 2Cleft lip corrected genetically in mouse model 2Cleft lip corrected genetically in mouse model 3Growth through innovations and open access: The journal ZooKeys on point for digital taxonomy 2
... Pichia Protocols is the first all-inclusive ... the Pichia pastoris Expression System. Methods developed ... provided as detailed, step-by-step protocols. This book ... expression vector, through strain construction and analysis, ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
Biology Products: